Gilead Sciences Inc (GILD) - News Archive

Gilead s ASCENT-07 Study Update: A Mixed Bag Amidst Competitive Pressure in the Pharmaceutical Sector Foster City, California - Gilead Sciences, Inc. (Nasdaq: GILD) has recently provided an update regarding its Phase 3...

Gilead Sciences, Inc. (Nasdaq: GILD) is positioning itself at the forefront of liver disease research with its upcoming presentation at The Liver Meeting 2025, an event organized by the American Association for the Stud...

In a pivotal leap for antiviral research and development, Gilead Sciences, Inc. (Nasdaq: GILD) is set to showcase groundbreaking findings at IDWeek 2025, scheduled from October 19-22 in Atlanta, GA. With a comprehensive...

In the rapidly evolving landscape of oncology, Gilead Sciences, Inc. and its subsidiary Kite are steadfastly positioning themselves as leaders in cancer care innovation. The recent European Society for Medical Oncology...

In an era where health and innovation intertwine, Gilead Sciences (Nasdaq: GILD) demonstrates a decisive commitment to enhancing its manufacturing capabilities while simultaneously addressing pressing global health chal...

In a landmark announcement, Gilead Sciences, Inc. (Nasdaq: GILD), a leader in biotechnology, has unveiled promising new data regarding lenacapavir (Yeztugo), a novel injectable medication poised to transform the landsca...

Gilead Sciences: Advancing Global Health Through Strategic Partnerships and Breakthrough Therapies In an era marked by urgent global health challenges, innovative pharmaceutical solutions are critical for enhancing heal...

In a significant advancement for cancer treatment, Gilead Sciences Inc. (NasdaqGS: GILD) has announced highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) for patie...

The treatment landscape for metastatic triple-negative breast cancer (mTNBC) has seen limited advancements, making any potential new therapies highly anticipated by both clinicians and patients. Recent data highlighting...

In a significant advancement for public health, Gilead Sciences, Inc. (Nasdaq: GILD) has made noteworthy strides in its drug development efforts, as evidenced by recent announcements regarding two of its investigational...

Unlocking the Future of Drug Discovery: Gilead and Terray Therapeutics Forge a Multi-Target Collaborative PathwayIn a high-stakes pursuit of innovative healthcare solutions, Gilead Sciences, Inc. and Terray Therapeutics...

Seladelpar Shines: Gilead Sciences Takes a Leap in Battling Primary Biliary Cholangitis In a significant stride for those battling liver diseases, Gilead Sciences, Inc. recently heralded a promising development: the Com...

Gilead Sciences: A Competitive Edge in HIV Prevention Amidst Mixed Financial PerformanceIn a significant stride for HIV prevention, Gilead Sciences, Inc. (NASDAQ: GILD) recently announced the publication of the full res...

Gilead Sciences, Inc. (Nasdaq: GILD), a leader in biopharmaceutical innovation, has announced promising data from the interim analysis of its ongoing Phase 3 ASSURE study. The data were revealed in a recent press releas...

FOSTER CITY, Calif. In a world constantly on the brink of medical breakthroughs, the recent announcement by Gilead Sciences, Inc. has caused ripples of optimism across the healthcare community. This is particularly true...

Unlocking New Horizons: Gilead’s Livdelzi Shines in PBC Treatment Amid Competitive Market Dynamics In the evolving landscape of hepatology, Gilead Sciences, Inc. (Nasdaq: GILD) continues to assert its presence, particul...

In a significant stride towards HIV prevention and treatment, Gilead Sciences, Inc. has unveiled promising results from two pivotal clinical trials. Recently presented data from the Phase 3 PURPOSE 2 trial showcases the...

Gilead Sciences at the Forefront of HIV Research and Investment Dynamics Gilead Sciences, Inc. a prominent player in the pharmaceutical industry, is underlining its commitment to ending the HIV epidemic as it prepares t...

Kite, a Gilead Company, is poised to make a significant impact at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH 2024), scheduled for December 7-10 in San Diego, California. The biopha...

Championing Antiviral Innovation: Gilead Sciences at IDWeek 2024 FOSTER CITY, Calif. As the global biotechnology leader Gilead Sciences Inc. prepares to take center stage at IDWeek 2024, anticipation builds around the t...